B34. ILD CELLULAR MECHANISMS最新文献

筛选

英文中文

A Prospective Randomized, Multicenter Trial Evaluating the Efficacy and Safety of Combined Therapy with Pirfenidone and Inhaled N-Acetylcysteine for Idiopathic Pulmonary Fibrosis 一项评估吡非尼酮和吸入n -乙酰半胱氨酸联合治疗特发性肺纤维化疗效和安全性的前瞻性随机多中心试验

B34. ILD CELLULAR MECHANISMS Pub Date : 2020-05-01 DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3064

K. Kataoka, S. Sakamoto, Yasuhiro Kondoh, Kazuhisa Takahashi, Tomoaki Hoshino, Hiroshi Mukae, Masashi Bando, T. Suda, T. Kido, Y. Tanino, T. Kishaba, Noboru Hattori, Yoshio Taguchi, T. Saito, Yasuhiko Nishioka, K. Kuwano, K. Kishi, N. Inase, Sei Sasaki, Hajime Takizawa, T. Johkoh, F. Sakai, S. Homma

引用次数: 0

Galactic-1: A Randomized, Double-Blind, Multicentre, Parallel, Placebo-Controlled Phase 2b Study in Subjects with Idiopathic Pulmonary Fibrosis (IPF) Investigating the Efficacy and Safety of TD139, an Inhaled Galectin-3 Inhibitor Administered via a Dry Powder Inhaler Over 52 Weeks Galactic-1:一项随机、双盲、多中心、平行、安慰剂对照的2b期研究，在特发性肺纤维化(IPF)患者中研究TD139的有效性和安全性，TD139是一种吸入式半乳糖凝集素-3抑制剂，通过干粉吸入器给药超过52周

B34. ILD CELLULAR MECHANISMS Pub Date : 2020-05-01 DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3065

A. Mackinnon, S. Khindri, N. Hirani, H. Leffler, U. Nilsson, T. Sethi, A. Pedersen, H. Schambye, C. McClinton, R. Slack, T. Maher

引用次数: 0

Upregulation of S100 Calcium Binding Protein A9 Levels in the Lungs of Patients with Idiopathic Pulmonary Fibrosis 特发性肺纤维化患者肺中S100钙结合蛋白A9水平的上调

B34. ILD CELLULAR MECHANISMS Pub Date : 2020-04-03 DOI: 10.21203/rs.3.rs-20772/v1

Jong-Uk Lee, Jong-Sook Park, Myung-Shin Kim, Jai-Seong Park, Eun-Suk Go, H. Chang, Choon S. Park

{"title":"Upregulation of S100 Calcium Binding Protein A9 Levels in the Lungs of Patients with Idiopathic Pulmonary Fibrosis","authors":"Jong-Uk Lee, Jong-Sook Park, Myung-Shin Kim, Jai-Seong Park, Eun-Suk Go, H. Chang, Choon S. Park","doi":"10.21203/rs.3.rs-20772/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-20772/v1","url":null,"abstract":"\u0000 Background: Neutrophilic inflammation is a predominant characteristic of idiopathic pulmonary fibrosis (IPF). S100 Calcium-Binding Protein A9 (S100A9) is a neutrophil-derived protein and is involved in the development of neutrophil-related chronic inflammatory disorders. However, the role of S100A9 in IPF has not been evaluated.Methods : S100A9 concentrations were measured by ELISA in the BAL fluid obtained from NCs (n = 33) and patients with IPF (n = 87), NSIP (n = 22), HP (n = 19), or sarcoidosis (n = 10).Results: The S100A9 levels in BALF were significantly higher in patients with IPF than in those with NC (0.4 [0.18–0.9] vs. 0 [0–0.5] ng/mL, p < 0.001), HP (0.19 [0.07–0.33] ng/mL, p = 0.043), or sarcoidosis (0.06 [0–0.11] ng/mL, p < 0.001) patients. A S100A9 level of 0.093 ng/mL had discriminating powers of 78.79% for specificity and 81.61% for sensitivity between IPF patients and NCs. S100A9 levels were also correlated with neutrophil numbers (r = 0.356, p = 0.0007) and S100A9 was expressed on neutrophils and macrophages in the BALF of IPF patients. Patients with S100A9 levels above 0.5535 ng/mL or a neutrophil percentage above 49.09% (n = 43) had significantly lower survival rates than those with S100A9 levels at or below 0.5535 ng/mL and a neutrophil percentage at or below 49.09% (n = 41) (HR, 9.28; p = 0.0004).Conclusion: S100A9 may participate in the development and progression of IPF. The levels of S100A9 in BALF may be a surrogate marker for diagnosing IPF and predicting its prognosis.","PeriodicalId":385960,"journal":{"name":"B34. ILD CELLULAR MECHANISMS","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122370831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0